Herantis Pharma (OHEL:HRTIS) FCF Yield %: -14.12 (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OHEL:HRTIS Herantis Pharma PLC OHEL:HRTIS
27 GF Score
Price €1.63
! 3 Warning Signs
View Full Analysis

What is Herantis Pharma FCF Yield %?

Herantis Pharma OHEL:HRTIS +4.49% 27 FCF Yield % is -14.12 as of Aug. 08, 2026. GuruFocus rates OHEL:HRTIS with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,409 Biotechnology companies, Herantis Pharma ranks worse than 60.75% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Herantis Pharma's Trailing 12-Month Free Cash Flow is €-6.10 Mil, and Market Cap is €43.20 Mil. Therefore, Herantis Pharma's FCF Yield % for today is -14.12%.

The historical rank and industry rank for Herantis Pharma's FCF Yield % or its related term are showing as below:

OHEL:HRTIS' s FCF Yield % Range Over the Past 10 Years
Min: -58.64   Med: -26.9   Max: -7.44
Current: -14.12


During the past 13 years, the highest FCF Yield % of Herantis Pharma was -7.44%. The lowest was -58.64%. And the median was -26.90%.

OHEL:HRTIS's FCF Yield % is ranked worse than
60.75% of 1409 companies
in the Biotechnology industry
Industry Median: -9.51 vs OHEL:HRTIS: -14.12

Herantis Pharma's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.


Herantis Pharma FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Herantis Pharma FCF Yield % Related Terms


Herantis Pharma FCF Yield % Historical Data

* Premium members only.

The historical data trend for Herantis Pharma's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Herantis Pharma FCF Yield % Chart

Herantis Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.01 -32.05 -14.60 -21.43 -12.40

Herantis Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.39 -18.14 -22.98 -21.39 -11.01

OHEL:HRTIS vs VRTX, REGN, RVMD: FCF Yield % Comparison

For the Biotechnology subindustry, Herantis Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Herantis Pharma FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Herantis Pharma's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Herantis Pharma's FCF Yield % falls into.


OHEL:HRTIS
27GF Score
Herantis Pharma PLC OHEL:HRTIS
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Herantis Pharma FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Herantis Pharma's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-6.095 / 49.1538
=-12.40%

Herantis Pharma's annualized FCF Yield % for the quarter that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-2.707 * 2 / 49.1538
=-11.01%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -14.12 mean?
Herantis Pharma (OHEL:HRTIS) has a FCF Yield % of -14.12 as of Aug. 08, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Herantis Pharma and its competitors. According to the industry distribution chart, Herantis Pharma ranks #856 out of 1409 companies in the Biotechnology industry, placing it in the top 60.8%.
Is Herantis Pharma's FCF Yield % too high?
Herantis Pharma's current FCF Yield % is -14.12. Based on the distribution chart, Herantis Pharma ranks #856 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Herantis Pharma has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Herantis Pharma's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Herantis Pharma ranks #856 out of 1409 companies for FCF Yield %. This places Herantis Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Herantis Pharma and its competitors. Herantis Pharma's current FCF Yield % is -14.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Herantis Pharma stock overvalued right now?
Herantis Pharma (OHEL:HRTIS) has a current FCF Yield % of -14.12. The current FCF Yield % is -14.12. Herantis Pharma's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Herantis Pharma (OHEL:HRTIS), the current FCF Yield % is -14.12 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Herantis Pharma Business Description

Address Bertel Jungin Aukio 1, Espoo, FIN, 02600
Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinsons disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.
27GF Score

Get the complete analysis for OHEL:HRTIS

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.63
Price